The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Updates in Juvenile Dermatomyositis: Pathogenesis & Patient Care

Updates in Juvenile Dermatomyositis: Pathogenesis & Patient Care

July 17, 2021 • By Jason Liebowitz, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Consider the diagnosis of clinically amyopathic dermatomyositis in patients who have had at least six months of skin rashes, such as a heliotrope rash, without obvious weakness, said Dr. Reed. Of these patients, about 25% will progress to juvenile dermatomyositis.1

You Might Also Like
  • European Group Offers Guidance on Managing Juvenile Dermatomyositis
  • Case Report: Digital Ulcers & Weight Loss in a Pediatric Patient
  • ACR/EULAR Response Criteria Approved for Adult, Juvenile Myositis
Explore This Issue
September 2021
Also By This Author
  • Sicca Sleuthing: Clinical Pearls for Diagnosing & Treating Sjögren’s Syndrome

The presence of myositis-specific antibodies can help clinicians screen for and predict specific manifestations of particular myositis phenotypes that may occur over time in patients’ lives. Examples:

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
  • Antibodies to nuclear matrix protein-2 (NXP2) correlate with calcinosis, contractures and significant skin involvement.
  • Antibodies to transcriptional intermediary factor-1γ (TIF-1γ) often predict severe cutaneous involvement, generalized lipodystrophy, photoerythema and psoriasiform lesions.
  • Antibodies to TIF-1γ in adults are associated with malignancy, but this association is not seen in children.
  • Antibodies to melanoma differentiation-associated gene 5 (MDA5) are associated with amyopathic disease, ulcerations of the skin and interstitial lung disease, which can be rapidly progressive.

Whenever possible, rheumatologists should seek to identify which myositis-specific antibodies are present in their patient and use this information to be proactive in delivering care to these patients, said Dr. Reed.

Treatment

No treatments have been approved by the U.S. Food & Drug Administration (FDA) for JDM. Many empiric treatments, which are based on expert recommendations and consensus treatment protocols, have significant side effects. But Dr. Kim said a few trials do exist on which to base treatment recommendations.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In a retrospective study of 60 patients with JDM who had received at least three months of treatment with a tumor necrosis factor (TNF) α inhibitor (i.e., infliximab or adalimumab), patients experienced improvements from baseline with respect to skin disease as measured by the modified skin disease activity score, physician’s global disease assessment and muscle disease as measured by the Childhood Myositis Assessment Scale (CMAS) and Manual Muscle Testing (MMT8).6

In a different retrospective study of 56 patients with JDM who received treatment with cyclophosphamide using the EuroLupus dosing protocol, patients experienced reductions in skin disease, global disease and muscle disease at months 6, 12 and 24, compared with their condition at the start of treatment.7

Finally, Dr. Kim presented intriguing evidence that Janus kinase inhibitors (jakinibs) may effectively treat JDM by blocking the interferon signaling pathway.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

With respect to medications, corticosteroids are recognized as an essential component of treatment for patients with JDM. Yet no widespread consensus exists on the exact dose and duration of corticosteroids to use in these patients. Similarly, questions remain as to which immunosuppressive agents, such as methotrexate, mycophenolate mofetil or rituximab, should be employed, as well as the sequence in which to try such therapies.

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Meeting Reports Tagged With: juvenile dermatomyositis, Pathogenesis, Pediatric Rheumatology, Pediatric Rheumatology Symposium, PRSYMIssue: September 2021

You Might Also Like:
  • European Group Offers Guidance on Managing Juvenile Dermatomyositis
  • Case Report: Digital Ulcers & Weight Loss in a Pediatric Patient
  • ACR/EULAR Response Criteria Approved for Adult, Juvenile Myositis
  • Case Report: A Patient with Clinically Amyotrophic Dermatomyositis & Associated ILD & RA Overlap

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)